Source: Annual Congress 2008 - Pathophysiology of pulmonary hypertension
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Tamby, B. Terrier, L. Camoin, P. Guilpain, C. Broussard, G. Bussone, A. Yaici, F. Hotellier, G. Simonneau, L. Guillevin, M. Humbert, L. Mouthon (Paris, Clamart, France). Identification of target antigens of anti-fibroblast antibodies in pulmonary arterial hypertension. Eur Respir J 2008; 32: Suppl. 52, 276

Member's Comments

No comment yet.

Related content which might interest you: Prevalence of anti-endothelial cell antibodies in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2010; 35: 923-925 Year: 2010 Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma Source: Eur Respir J 2012; 39: 1405-1414 Year: 2012 Anti-endothelial cell antibodies in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 339s Year: 2006 Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension Source: Eur Respir J 2006 Oct 01;28(4):799-807 Year: 2006 Survivin inhibition as a potential target for pulmonary arterial hypertension Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench Year: 2019 CD133+ cells in pulmonary arterial hypertension Source: Eur Respir J 2016; 48: 459-469 Year: 2016 Targeting BMPR-II in pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary arterial hypertension: future therapeutic approaches Year: 2016 Multi-omic profiling in pulmonary arterial hypertension Source: Virtual Congress 2020 – Genetics and genomics of pulmonary arterial hypertension Year: 2020 Targeting cell motility in pulmonary arterial hypertension Source: Eur Respir J 2014; 43: 531-544 Year: 2013 Increased platelet reactivity and thrombogenesis in pulmonary arterial hypertension subgroups Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases Year: 2009 Targeting HIF2a-ARNT hetero-dimerisation as a novel therapeutic strategy for pulmonary arterial hypertension Source: Eur Respir J, 57 (3) 1902061; 10.1183/13993003.02061-2019 Year: 2021 PSGR olfactory receptor: A new potential target in pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016 Regulation of Type I cytokine receptors as a target for pulmonary arterial hypertension treatment? Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Analysis of pulmonary endothelial microparticles, haemodynamics and functional class in pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 RNA expression pattern of peripheral blood B-lymphocytes in idiopathic pulmonary arterial hypertension Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension Year: 2007 Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target Source: Eur Respir J 2011; 38: 1453-1460 Year: 2011 Immune repertoire-based signatures in pre-capillary pulmonary hypertension Source: International Congress 2018 – Pathobiology of pulmonary hypertension Year: 2018 CD163 is expressed and modulated in human pulmonary artery smooth muscle cells: Implications for pulmonary artery hypertension Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015 Endothelial-derived MIF contributes to pulmonary endothelial cell proliferation in human pulmonary arterial hypertension Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015